Cancer Biopsy Market Size

Cancer Biopsy Market Size

Cancer Biopsy Market size was valued at USD 21.5 billion in 2023 and is estimated to grow at a CAGR of 8.4% from 2024 to 2032. The market has witnessed significant growth driven by the increasing prevalence of cancer and advancements in cancer diagnostic technologies, including biopsies.

To get key market trends

  Download Free Sample

Innovative techniques such as liquid biopsy and next-generation sequencing (NGS) have attracted attention due to their high precision and minimally invasive nature. These technological advancements in cancer biopsy procedures are transforming cancer diagnostics by providing less invasive and more accurate methods for detecting and monitoring the disease. For instance, in 2019, the National Cancer Institute (NCI) reported that liquid biopsies can identify genetic mutations in over 70% of advanced cancer cases. This result aimed to enhance early detection, support personalized treatment strategies, and improve patient outcomes.

Furthermore, the increasing awareness of inherited oncology disorders and genetic testing is further driving demand. These technologies enable early detection and personalized treatment, resulting in improved patient outcomes. This has led to a growing emphasis on targeted cancer therapies that leverage insights gained from advanced biopsy techniques for diagnosis.

A cancer biopsy is a medical procedure that involves obtaining a tissue or cell sample from a suspicious area in the body to determine the presence of cancer. This process includes various methods such as needle biopsies, surgical biopsies, and liquid biopsies. The market encompasses both products, such as biopsy instruments and kits, and services, including diagnostic testing and analysis.